logo-loader
viewArix Bioscience PLC

Roth repeats Buy rating on Arix Bioscience's portfolio company Harpoon Therapeutics

The Buy rating comes after Harpoon granted phama giant Abbvie an exclusive option over the rights to a treatment for a type of blood cancer

Arix Bioscience PLC - Arix Bioscience PLC’s portfolio company Harpoon Therapeutics gets Buy rating from Roth Capital Partners
The drug, HPN217, uses Harpoon’s technology to target BCMA, a biomarker associated with multiple myeloma cancer

Roth Capital repeated a Buy rating on Arix Bioscience PLC’s (LON:ARIX) portfolio company Harpoon Therapeutics (NASDAQ:HARP) after it granted phama giant Abbvie (NYSE:ABBV) an exclusive option over the rights to a treatment for a type of blood cancer.

The drug, HPN217, uses Harpoon’s Tri-specific T cell Activating Construct (TriTAC) technology to target BCMA, a biomarker associated with multiple myeloma cancer.

This latest agreement builds on a collaboration deal signed in 2017 and also gives Abbvie exclusive rights to develop and market two new TriTAC molecules plus an option to select up to four additional targets.

READ: Arix Bioscience portfolio company Harpoon agrees US$2.4bn deal with Abbvie

For each of the targets, Harpoon will receive a milestone payment of $310 million each upfront plus royalties on global sales.

Harpoon will receive $50 million upfront for the option over HPN217 and a further $50 million when the first patient is treated in a clinical trial, though the licence and option agreement represents a potential transaction value of up to $510 million including royalties. 

“We believe that this is a strong indication of Abbvie's confidence in the platform, a superb strategic move for Harpoon to remain focused on its solid tumor efforts, and an excellent source of additional cash (up to $100M likely to be received between now and 1H2020),” wrote analyst Zegbeh Jallah.  

The analyst also noted that with regards to the commercial milestone payments of $310 million each, “we've seen several of these agreements in the bispecific space and believe that this is a competitive offer for Harpoon, and we also remind investors that for the discovery agreement, following the discovery phase, AbbVie is solely responsible for the development, manufacturing and commercialization of productions that arise from the agreement.”

Roth maintains a $25 price target on Harpoon shares, which recently traded up slightly to $15.40 in New York. 

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham


 

Quick facts: Arix Bioscience PLC

Price: 112.5 GBX

LSE:ARIX
Market: LSE
Market Cap: £152.5 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Arix Bioscience PLC named herein, including the promotion by the Company of Arix Bioscience PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Aura Biosciences reports positive clinical data on its eye cancer treatment...

Aura Biosciences Inc CEO Elisabet de los Pinos tells Proactive Investors the biotech has reported positive clinical data from its Phase 1b/2 clinical trial evaluating the safety and efficacy of light- activated AU-011, its lead product candidate for the treatment of choroidal melanoma, a type...

on 11/06/2018

2 min read